In the claims:

Please cancel claims 14 and 15 without prejudice to applicants' right to pursue the subject matter of these claims in a future application.

Please amend claims 1, 17 and 25 as follows:

--1.(amended) A method for treating or preventing stroke in a human subject wherein the subject is susceptible to intracranial hemorrhaging, comprising administering a CD39 polypeptide (SEQ ID NO. 1) or an active fragment thereof which inhibits adenosine diphosphate-mediated platelet aggregation by increasing adenosine diphosphate catabolism to the subject, without increasing incidence of intracerebral hemorrhage in the human subject.--

--17.(amended) A method for determining whether a compound inhibits platelet aggregation or leukocyte accumulation by increasing ADP catabolism and does not increase incidence of intracerebral hemorrhage, so as to treat or prevent thrombotic or ischemic disorders in a subject, comprising:

(a) inducing thrombotic or ischemic disorders in an animal, which animal is an animal model for thrombotic or

ischemic disorders;

(b) measuring the stroke outcome in said animal and the incidence of intracerebral hemorrhage in said animal,

(c) measuring platelet deposition and/or fibrin deposition in ischemic tissue, and

(d) comparing the stroke outcome [in step (b)] and the platelet deposition and/or fibrin deposition with that of the animal model in the absence of the compound so as to identify a compound capable of treating or preventing thrombotic or ischemic disorders in a subject.--

--25. (amended) A pharmaceutical composition ~~comprising~~ the compound of ~~claim~~ 21 and a pharmaceutically acceptable carrier as an agent to treat thrombotic or ischemic disorders in a subject without increasing incidence of intracerebral hemorrhage.--

REMARKS

Claims 1-26 are pending and under examination. Applicants have amended claims 1, 17 and 25 to include the phrase "without increasing the incidence of intracerebral hemorrhage in the animal" in order to more specifically claim the subject matter of the invention. Support for this amendment may be found *inter alia*, on